Finances Archives

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…

Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…

New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing…

The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…